Antiangiogenic therapy in patients with HER2-positive metastatic breast cancer: a case series

Clin Breast Cancer. 2014 Jun;14(3):e89-94. doi: 10.1016/j.clbc.2013.11.005. Epub 2013 Nov 21.

Authors

Olivia Le Saux¹, Benoît You², Gilles Freyer²

Affiliations

¹ Department of Medical Oncology, Centre Hospitalier Lyon-Sud, Pierre-Bénite, France. Electronic address: [email protected].
² Department of Medical Oncology, Centre Hospitalier Lyon-Sud, Pierre-Bénite, France.

PMID: 24424314
DOI: 10.1016/j.clbc.2013.11.005

No abstract available

Keywords: Aflibercept; Bevacizumab; HER2-positive; Metastatic breast cancer.

Publication types

Case Reports

MeSH terms

Adult
Angiogenesis Inhibitors / therapeutic use*
Antineoplastic Agents / therapeutic use
Breast Neoplasms / blood supply
Breast Neoplasms / drug therapy*
Breast Neoplasms / genetics
Breast Neoplasms / pathology
Carcinoma, Ductal, Breast / blood supply
Carcinoma, Ductal, Breast / drug therapy*
Carcinoma, Ductal, Breast / genetics
Drug Therapy, Combination
Female
Humans
Middle Aged
Neoplasm Metastasis
Receptor, ErbB-2 / genetics

Substances

Angiogenesis Inhibitors
Antineoplastic Agents
Receptor, ErbB-2